AMGN

SEC source: 0001127602-21-015362 · form4.xml · nonDerivative · entry 3

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,266

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 58 RSUs which will vest on 4/27/2022; 132 RSUs which vest in installments of 65 on 5/3/2022 and 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment of 495 on 11/2/2024; and 300 RSUs which vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 42 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015364 · form4.xml · nonDerivative · entry 3

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,787

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 326 RSUs which will vest on 4/27/2022; 1,133 RSUs which will vest in installments of 558 on 5/3/2022 and 575 on 5/3/2023; 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024; and 709 RSUs which vest in installments of 233 on 4/30/2023, 234 on 4/30/2024 and 242 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-21-015366 · form4.xml · nonDerivative · entry 3

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,472

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 345 RSUs which will vest on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 3,023 RSUs which will vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 953 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015368 · form4.xml · nonDerivative · entry 3

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,108

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,645 RSUs which vest in installments of 1,303 on 5/3/2022 and 1,342 on 5/3/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,964 RSUs which vest in two installments of 1,308 on 4/30/2023 and 4/30/2024 and 1,348 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 351 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015045 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 597,023

SEC source: 0001127602-21-015352 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,181

SEC source: 0001127602-21-015358 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,516

SEC source: 0001127602-21-015360 · form4.xml · nonDerivative · entry 2

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,700

SEC source: 0001127602-21-015362 · form4.xml · nonDerivative · entry 2

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,283

SEC source: 0001127602-21-015364 · form4.xml · nonDerivative · entry 2

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,007

SEC source: 0001127602-21-015366 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,217

SEC source: 0001127602-21-015368 · form4.xml · nonDerivative · entry 2

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,793

SEC source: 0001127602-21-015041 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,256.4421

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 240 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015043 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,093.618

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 431 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015045 · form4.xml · derivative · entry 4

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,307

Underlying: Common Stock · 115,307 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015045 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 599,925

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015350 · form4.xml · derivative · entry 3

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,231

Underlying: Common Stock · 36,231 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015350 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,630

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015352 · form4.xml · derivative · entry 4

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,971

Underlying: Common Stock · 32,971 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015352 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,762

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015356 · form4.xml · derivative · entry 2

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,985

Underlying: Common Stock · 28,985 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015356 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,960

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 18,352 RSUs which vest in two installments of 6,056 on each of 11/1/2021 and 11/1/2022 and one installment of 6,240 on 11/1/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 886 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-21-015358 · form4.xml · derivative · entry 5

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,072

Underlying: Common Stock · 5,072 shares

Expires 2031-04-30

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015358 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,578

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015360 · form4.xml · derivative · entry 4

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,623

Underlying: Common Stock · 28,623 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015360 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,055

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015362 · form4.xml · derivative · entry 4

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,608

Underlying: Common Stock · 2,608 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015362 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,301

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015364 · form4.xml · derivative · entry 4

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,159

Underlying: Common Stock · 6,159 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015364 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,146

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015366 · form4.xml · derivative · entry 4

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,782

Underlying: Common Stock · 34,782 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015366 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,326

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015368 · form4.xml · derivative · entry 5

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,420

Underlying: Common Stock · 34,420 shares

Expires 2031-04-30

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015368 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,444

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-014594 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 586,645

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,019 RSUs which will vest on 5/1/2021; 4,790 RSUs which will vest on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-014597 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,965

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 RSUs which will vest on 5/1/2021; 1,073 RSUs which will vest on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 897 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-014599 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,994

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which will vest on 5/1/2021; 153 RSUs which will vest on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 247 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-014601 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,759

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which will vest on 5/1/2021; 690 RSUs which will vest on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 682 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-014603 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,001

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 63 RSUs which will vest on 5/1/2021; 58 RSUs which will vest on 4/27/2022; 197 RSUs which vest in two installments of 65 on 5/3/2021 and 5/3/2022 and one installment of 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; and 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment of 495 on 11/2/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 52 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-014605 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,437

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 335 RSUs which will vest on 5/1/2021; 326 RSUs which will vest on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 206 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-21-014607 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,320

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,673 RSUs which will vest on 5/1/2021; 335 RSUs which will vest on 5/1/2021; 345 RSUs which will vest on 4/27/2022; 8,597 RSUs which vest in installments of 4,234 on 11/2/2021 and 4,363 on 11/2/2022; 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,280 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-014609 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,480

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,171 RSUs which will vest on 5/1/2021; 1,073 RSUs which will vest on 4/27/2022; 3,947 RSUs which vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023; and 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 567 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-013759 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2022-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-013759 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,927

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 2,264 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-013759 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-011708 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 589,262

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,019 RSUs which vest on 5/1/2021; 9,439 RSUs which vest in installments of 4,649 on 4/27/2021 and 4,790 on 4/27/2022; 15,791 RSUs which vest in two installments of 5,211 on 5/3/2021 and 5/3/2022 and one installment of 5,369 on 5/3/2023; and 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,728 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011709 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,458

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,194 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011710 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,529

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 990 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011711 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,051

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 260 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011712 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,104

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 742 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.